SLV 341Alternative Names: SLV341
Latest Information Update: 05 Feb 2013
At a glance
- Originator Genfit; Solvay Pharmaceuticals
- Developer Abbott Laboratories; Genfit; Solvay Pharmaceuticals
- Mechanism of Action Cytoplasmic and nuclear receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Phase I Type 2 diabetes mellitus